Evidence map›Paper›PMID 39385659›Full record

ArticleAdvanced healthcare materials2025

Precision Photothermal Therapy at Mild Temperature: NIR-II Imaging-Guided, H

Gongcheng Ma, Qihang Ding, Yue Wang, Zhiwei Zhang, Yuding Zhang, Hui Shi, Lintao Cai, Ping Gong, Pengfei Zhang, Zhen Cheng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gongcheng MaSchool of Life Science and Technology, Xinxiang Medical University, Xinxiang, 453003, P. R. China.
Qihang DingDepartment of Chemistry, Korea University, Seoul, 02841, South Korea.ORCID https://orcid.org/0000-0002-2665-9036
Yue WangGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Zhiwei ZhangGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Yuding ZhangGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Hui ShiState Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, P. R. China.
Lintao CaiGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Ping GongGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Pengfei ZhangGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, CAS Key Laboratory of Biomedical Imaging Science and System, Shenzhen Engineering Laboratory of Nanomedicine and Nanoformulations, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Zhen ChengState Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, P. R. China.
Jong Seung KimDepartment of Chemistry, Korea University, Seoul, 02841, South Korea.ORCID https://orcid.org/0000-0003-3477-1172

Funding

Guangdong Basic and Applied Basic Research Fund Project 2019A1515110222Guangdong Basic and Applied Basic Research Fund Project 2021A1515110699Guangdong Provincial Key Area R&D Program 2020B1111540001Major Instrumentation Development Program of the Chinese Academy of Sciences ZDKYYQ20220008National Key R&D Programs 2021YFA0910001 2023YFA0915402National Natural Science Foundation of China 22105057National Natural Science Foundation of China 32000982National Natural Science Foundation of China 81901906National Research Foundation of Korea 2018R1A3B1052702Shandong Laboratory Program SYS202205Shenzhen Basic Research JCYJ20200109114616534Shenzhen Basic Research JCYJ20210324115804013Shenzhen Basic Research JCYJ20210324120011030Shenzhen-Macao Technology Plan SGDX2020110309280301Shenzhen Science and Technology Program KQTD20210811090115019Technological Cooperation Projects 2020A0505100047Zhuhai Innovation and Entrepreneurship Team Project ZH01110405180056PWC
6 · The paper itself

Abstract

The therapeutic efficacy of photothermal therapy (PTT) under mild temperatures (<45 °C) is hindered as cancer cells can activate heat shock proteins (HSPs) to mend fever-type cellular damage swiftly. The previous attempt fabricated first-generation nanobombs (nanobomb1G) by self-assembly of polymeric NIR-II AIEgens and carbon monoxide (CO) carrier polymer mPEG(CO) to inhibit the expression of HSPs after intratumor injection. A new generation nanobomb (Stealth NanoBomb (SNB)) is developed by self-assembling small molecular NIR-II AIEgens with CO carrier polymer PLGA(CO) coated by PEG-lipid. This design allows for intravenous administration, enabling the SNB to circulate safely in the bloodstream and selectively target cancer cells. Upon accumulation in tumors, the SNB releases CO to effectively suppress HSP expression, enhancing the therapeutic efficacy of mild-temperature PTT. Compared to the previous generation, the SNB offers a safer, more stable, and more efficient CO gas/drug co-delivery system for cancer treatment. This work represents a significant advancement in PTT, providing a promising strategy for enhanced antitumor therapy with reduced systemic toxicity.

Indexed as

Hydrogen PeroxideNanoparticlesPhotothermal TherapyAnimalsCarbon MonoxideCell Line, TumorHumansInfrared RaysMiceMice, Inbred BALB CMice, NudeNeoplasmsPolyethylene GlycolsTemperatureCarbon MonoxideHydrogen PeroxidePolyethylene Glycolsaggregation‐induced emissioncarbon monoxideheat shock proteinsmild‐temperature photothermal therapyNIR‐II imaging

Identifiers

PMID39385659
PMCPMC12506850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.